Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic

Rosi, Elia; Fastame, Maria Thais; Cesare, Antonella Di; Silvi, G; Pimpinelli, Nicola; Prignano, Francesca

doi:10.3390/jcm10245841

Cited by 3 publications

(1 citation statement)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Te COVID-19 infection's impact on the worsening efect of psoriasis remains a hot topic. Previous research suggested that no adherence to the biologics was related to the psoriasis fare-up [22]. Although the infection of SARS-CoV-2 might play a crucial direct role in psoriasis aggravation, the pieces of literature about it were mainly presented as cases.…”

Section: Discussionmentioning

confidence: 99%

The Characteristics of COVID‐19 Symptoms and Skin Manifestations among Nonhospitalized COVID‐19 Patients with Psoriasis during the Omicron Pandemic in China: A Single‐Center Survey‐Based Study

Xiao,

Zhang,

Feng

et al. 2023

Dermatologic Therapy

View full text Add to dashboard Cite

Background. The global impact of coronavirus 2019 (COVID-19) has raised concerns about the management of psoriasis patients, especially among those using biologics. Methods. We conducted a survey-based research among Omicron-infected (confirmed, probable, and suspected ones) psoriasis patients in the department of dermatology, West China Hospital, Sichuan University, from January 9th to January 22nd, 2023. We collected demographic and clinical information (psoriasis- and COVID-19-related) and conducted statistics analysis. Results. Of the 240 patients enrolled, they were classified by the psoriatic treatment, as biologics (n = 138), nonbiological systematic treatment (n = 52), and topical treatment or without pharmacological treatment (n = 50). This study showed the characteristics of Omicron-related symptoms and cutaneous signs in patients. We observed that patients who received topical treatment or without pharmacological treatment had a lower risk of presenting with COVID-19 symptoms in the fully adjusted logistic model (OR = 0.40, 95% CI: 0.18–0.90, and P=0.025). Moreover, in the model for skin manifestations, nonbiological systematic treatment (OR = 2.15, 95% CI: 1.08–4.27, and P=0.029) and high BMI (OR = 1.10, 95% CI: 1.00–1.20, and P=0.042) were correlative factors. Conclusions. Our data suggested that differential psoriatic treatment might be a correlative factor in developing symptomatic or asymptomatic Omicron infection and presenting cutaneous signs.

show abstract

Section: Discussionmentioning

confidence: 99%